Download Medical Notes on Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review

Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review Medical Notes

About This Presentation

Description:The year 2019 was a good year for biopharma, fueled by strong fourth quarter markets and deal making. After difficult 2018, the biopharma industry recovered commendably to do good in the year 2019. A fourth-quarter surge on the stock markets meant that many biopharma companies concluded the year on a good note, as investors ran to drug developers of all sizes. As far as medtech is concerned, with rise in big- and mid-cap share prices outpaced many best companies in biopharma. However, fourth quarter was difficult for medtech with IPO numbers declining and fewer FDA approvals. This made it a mixed year for the medtech sector. Download and check this Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review to understand which areas are doing good and which are struggling, as well as what this means for biotech and medtech in 2020.

Tags:Pharma, Biotech, Medtech, pharmaceutical, biopharma

Published on: Jun 29, 2020 | Views : 1841 | Downloads : 1

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

Cancer Medicines: Value in Context

High-Performance Pharma Brand Plans - The 5 Pitfalls to avoid

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 3

Managed Care Models: The Benefit vs. Cost Balance

Indian Biotechnology Industry Analysis by IBEF

Evaluate Vantage Report on impact of COVID-19 Biopharma and Medtech

Global pharma and Indian pharmaceutical industry: Prospects for growth

EvaluatePharma Orphan Drug Report 2020

Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations

Hospital Pharmacy Compliance Handbook

HEALTH A TO Z